Grants>Chronic Diseases

Rosalinde Gilbert Innovations in Alzheimer’s Disease Caregiving Legacy Awards

With continuing support from The Rosalinde and Arthur Gilbert Foundation, Family Caregiver Alliance (FCA) is pleased to oversee the annual Rosalinde Gilbert Innovations in Alzheimer's Disease Caregiving Legacy Awards program in its sixth year.

Three awards of $20,000 each will be awarded to nonprofit organizations, government agencies or universities responding to a community need with a program or project which focuses primarily on family/informal caregivers of adults with Alzheimer's disease and related dementias. Only agencies operating within the continental United States are eligible to apply. One award will be granted in each of these categories:

Creative Expression: This award will go to programs or projects that use imaginative and creative approaches in supporting persons with dementia or family/informal caregivers of persons with Alzheimer's disease and related dementias. Some examples are programs or projects using art, music, theatre, journaling, multimedia (e.g. film, documentary, radio) or other types of creative expression.

Diverse/Multicultural Communities: This award will go to programs or projects that provide services, support or other types of outreach to family/informal caregivers of persons with Alzheimer's disease or related dementias in diverse ethnic, age diversity, religion/spirituality, gender, rural, low income, and LGBT or other communities.

Policy and Advocacy: This award will go to programs or projects that advocate for systems change for the benefit of family/informal caregivers or care recipients with Alzheimer's disease or related dementias. These efforts could focus on legislation, executive or administrative changes, advocacy campaigns, or any other action to strengthen the public or private sector's recognition and support of family/informal caregivers.

Award Timeline

Applications are available, online only. The closing deadline for 2013 applications is 5 p.m. (Pacific Time), Friday, August 16, 2013. Award announcements will be made by late November 2013. Award recipients will be honored at the 2014 Annual Conference of the American Society on Aging (ASA). Participates will be invited to present information about their awarded program or project at the conference. Travel stipends will be available for the conference.

Eligibility and Submission Conditions

Nonprofit organizations, government agencies and universities responding to a community need with a program or project that focuses primarily on family/ informal caregivers of adults with Alzheimer's disease and related dementias are eligible to apply. Family or informal caregivers are unpaid caregivers. The term includes family members, friends, domestic partners and neighbors. Support for family/informal caregivers need not be the primary mission of the organization, agency or university.

Nonprofit applicants must submit proof of their 501(c) (3) status or other nonprofit status by attaching a copy of their nonprofit designation letter to their application. For-profit entities are not eligible to apply.

The nominated program or project has to have been active during the calendar year of 2012 and/or 2013. If the program or project involves a major culminating event, that event must have occurred prior to application deadline.

For the Policy & Advocacy and Creative Expression categories, program or project may be related to either family/informal caregivers or persons with dementia or both.

For the Diversity/Multicultural Communities category, program/project must be specific to family/informal caregivers of persons with Alzheimer's disease or related dementias.

The applicant or other designated program or project representatives must be willing to share information about their program with others, including a presentation at a national professional conference, and to write up additional information to appear on FCA's website and/or future publications. Award recipients may also be asked to provide information about how the award was used to further advance the mission of the organization, agency, or university.

Application must be received by the extended deadline of 5 p.m. (Pacific Time), on Friday, August 16, 2013.

Applicants must apply electronically using the designated online system.

Applicants must designate the category in which they would like to be considered. Applicants are competing only against others within their chosen category. If the judges feel that the applicant would be better suited for another category, they will contact the applicant directly.

Cystinosis Foundation Deanna Lynn Potts Scholarship

Deanna Lynn Potts was born with Cystinosis and lived to be 27 years old. Before she died, she discussed her wishes to start a scholarship fund for children with Cystinosis.

We know how devastating a chronic illness can have on a family emotionally, physically, socially, and financially. Children with Cystinosis are living longer, thanks to medical science and therefore, embarking on careers.

These careers require education. Education is expensive, yet something we do not want to deprive our children of in our world today. Due to the financially draining medical costs, it might prove difficult to send a child to college.

Through this fund, we hope to help some of those students.

PURPOSE: To provide supplemental financial assistance to an undergraduate student diagnosed with Cystinosis enrolled in an accredited collegiate or vocational program.

SCHOLARSHIP AWARD: A $1000 scholarship awarded annually. The award is contingent upon the winners acceptance to an accredited college, university, or vocational program and will be payable to the education institution to be applied to tuition, room and board.

ELIGIBILITY: Each candidate must be a current high school senior, who has Cystinosis and have a financial need.

APPLICATION PROCEDURE:

Documentation/verification of Cystinosis (e.g. letter from physician.)

An official copy of high school transcript.

Two letters of recommendation from current teachers/faculty members and/or counselors regarding applicant's scholastic aptitude and personal qualifications.

An essay of 500 words. We want to know a person who has played a vital role in student's life. How? Why? The essay should be typewritten and double spaced

A copy of the previous year's income tax return.

JUDGING CRITERIA: The essay will earn a possible 40 points and will be judged on the basis of rationale, grammar and comprehension. Transcripts and letters of recommendation will carry a possible additional 20 points. The Cystinosis Foundation Board will establish an independent judging panel to evaluate and rate the applicants. The decision of the judges is final. Finalists may be interviewed before selection is made.

DEADLINE FOR APPLICATION: Application and all accompanying documents must be received at the Cystinosis Foundation Office in a single, flat package by March 30th of each year. You can call the Cystinosis Foundation for an application 888-631-1588.

Remember, the deadline for receiving applications is March 30th of each year.

Request for Application: Cutaneous Lymphoma Foundation’s CLARIONS Research Awards Program

The signature funding initiative of the Research Awards Program (RAP), is the CLARIONS Grant Program, which stands for Curing Cutaneous Lymphoma by Advancing Research, Innovation and Offering New Solutions.  This research grant program supports investigators interested in conducting innovative cutaneous lymphoma research.   These grants will help uncover causes and improve the treatment and quality of life for patients. Discovering new avenues for better therapies and, one day, a cure for cutaneous lymphoma are key goals of this program.

Research Funding Priorities

Eligibility and Requirements

Investigators at all levels, from clinical and post-doctoral fellows to established investigators, are eligible to receive
awards. Medical students and graduate students are not eligible. Non-U.S. investigators are eligible and the research funded by the RAP can be conducted at non-U.S. institutions. Investigators must be members of an established and recognized academic institution. All research projects involving human subjects must receive IRB approval.

Award Amounts

Each year the CLF will provide two $25,000 awards, renewable for 1 year contingent upon approval by the CLF
Board of Directors based upon the CLF Scientific Review Board’s review and recommendation.

A small indirect cost amount between $1,000-$2,000 is allowable.

The CLF’s RAP seeks to fund innovative research in all areas of cutaneous lymphomas with particular interest in:

-- Etiology and risk factors of cutaneous lymphomas.

-- Measures of disease impact on individuals and populations affected by cutaneous lymphomas.

-- Translating discoveries into diagnostic and therapeutic advances in cutaneous lymphomas.

-- Optimizing therapies for cutaneous lymphomas.

-- Improving quality of life for individuals with cutaneous lymphomas

2013 Calendar of Award Events

January 31 -  Public announcement of Request for Application (RFA)

July 31 -  Application deadline

August - October - Scientific Review Board review

November - Recipients notified of award

December - Grant awards announced at ASH meeting

January, 2014 - Disbursement of Award and beginning of new award cycle

Cutaneous Lymphoma Foundation
PO Box 374
Birmingham, MI 48012-0374

Telephone: 248-644-9014

Fax: 248-644-9014

Call for Research Grant Applications: Cicatricial Alopecia Research Foundation

The Cicatricial Alopecia Research Foundation (CARF) seeks original, focused, and innovative research grant applications dealing with primary cicatricial alopecia (PCA). Applications will be accepted from laboratories around the world. The proposed project must serve to further CARF's research goals, namely, to understand the pathogenesis of PCA, an understanding that will lead to effective prevention and therapy. CARF will give priority to research proposals based on the following topics.

Role of lipids and lipid metabolism in normal hair follicle stem cell biology and cycling

Role of PPARs and other lipid regulators in the pathogenesis of PCA

Role of peroxisomes in hair follicle biology

Role of neuroinflammation in PCA

Role of environmental triggers in the pathogenesis of PCA

Function of sebaceous glands in normal hair follicle biology.

Mechanism of hair shaft egress from the terminal hair follicle

Hair follicle regeneration in a site of tissue repair

GUIDELINES: All applications for grant requests should clearly state research goals, rationale, brief background, and brief experimental protocol. The planned study may not exceed two years in duration. Included in the submission should be a discussion of anticipated results and their potential significance to understanding PCA. Typical awards are $5,000 to $20,000.

A final progress report must be submitted at the end of the funding period. A progress report must be submitted at the end of the first year to obtain a second year no-cost extension. CARF must be acknowledged on all presentations and publications resulting from CARF funded grants.

Applications are reviewed and funded on an annual basis.

Annual application deadline: March 15. Funding decisions made by June 15.

Call for Cancer Projects: Repurposing of Drugs - Breakthrough in Cancer Treatment

Funding Cancer Projects

Reliable Cancer Therapies (RCT) announces € 300 000 for projects repurposing existing drugs for cancer treatment.  The drugs must have been developed and approved for other indication(s). Relevant clinical trial endpoints (cancer survival & tumor response) should be the primary research assessments.

RCT also promotes collaborative research projects between researchers at different universities and/or organisations.

About the Call for Applications

• Medical Degree required for Principal Investigator (PI) or co-PI

• 1 application per PI

• Resubmission is allowed (please indicate the reason for previous decline)

• Set up of proposal:

◦ Application form: maximum 2 pages

◦ in appendix 1: biography & references of the PI and co-PI

◦ in appendix 2: overview of the budget (including salaries, supplies, equipment, patient care costs, and other expenses).

• If your cancer project is selected in the first round, detailled information will be requested for consideration of the final award selections.

• Approved proposals will be supported with a maximum of  € 300 000 for 3 years.

Reliable Cancer Therapies (RCT) is a non-profit organization based in Switzerland that provides research-based information on cancer therapies and selectively funds the development of promising therapies.

RCT investigates information on cancer therapies for evidence to then inform the public about evidence-based cancer treatment choices. We help cancer patients and caregivers to structure and absorb the complex nature of cancer information for their decision-making on registered complementary or alternative therapies.

RCT is continuously looking for cancer therapies that have never been thoroughly examined and consider financing cancer treatments that can be deemed promising based on measurable results.

Application Deadline

Application deadline is June 28, 2013 at 8am GMT. Incomplete or late applications will not be considered.

Please submit applications to Ann-Christine Moenaert (info@reliablecancertherapies.com)

RCT will review the applications internally with the support from our appropriate external experts by August 14, 2013. If the project is selected in the first round, more detailled information will be requested by September 13, 2013.  Final decisions will be made on October 4, 2013.

Contacts at RCT

Please direct any technical questions to Ann-Christine Moenaert (info@reliablecancertherapies.com)

Please contact Gauthier Bouche, MD (info@reliablecancertherapies.com) for any clinical or scientific questions.

American College of Cardiology Foundation/Merck Research Fellowships in Cardiovascular Disease

Four one-year fellowships will be awarded to support research in adult cardiology. Preference is given to individuals who have had no more than two years of prior full-time experience either in clinical or basic research. Recipients will be expected to pursue a full-time project in clinical research during their year of supported training.

Research Focus: In selecting applications, proposals addressing CVD and Cardiometabolic disorders are encouraged. Included are proposals that address pathophysiology, molecular genetics, metabolic abnormalities leading to cardiovascular disease, hypertension, heart failure, hyperlipidemia, inflammatory mechanisms and new pathways for drug discovery. Proposals focusing on clinically relevant outcomes as a result of the metabolic syndrome, diabetes or obesity are also encouraged. Outcomes studies should focus on clinical/and or systems of care (e.g., quality improvement) interventions, and use outcomes measures of importance to both patients and society, including mortality, significant morbidity or quality of life changes, or economic effects.

Preference for one award will be given to applicants focusing on disparities of care.  Despite increased attention to health disparities at the national, state and community levels, relatively little progress has been made in achieving the vision of eliminating racial and ethnic health disparities.  Since the rates of cardiovascular mortality in the United States are significantly higher for these patients and this is, in fact, the leading cause of death in this demographic, innovative approaches to eliminating these disparities are critical.  In an effort to encourage and support research in this area, proposals will be encouraged that focus on gender, race, geographic, and economic inequalities in cardiovascular care.

Eligibility: Anyone currently in an adult cardiology fellowship training program recognized by the Accreditation Council for Graduate Medical Education or the American Osteopathic Association and who has the recommendation and agreement of his/her training program director and institution.

Selection: Judging will be by the ACCF/Research Fellowship Awards Committee. Criteria for selection will include:

• Scientific quality of the project;

• Relevance to the research focus as described above;

• Qualifications and commitment of the applicant; and

• The quality of the training environment.

Successful applicants may pursue this protected year of research either within or following their three years of required training. Preference will be given to individuals who:

• Will pursue clinical research training and experience directly involving patients or human subjects.

• Have had no more than two years of prior full-time research experience either in clinical or basic research.

• Will not hold another major external fellowship or salary award, (e.g., from the National Institutes of Health or the American Heart Association) during the ACCF/Merck funded year.

The Award: Four fellowships in the amount of $70,000 each, to be used for salary support, for one year of research to begin July 1, 2014 and run through June 30, 2015.

Funding Source: The ACCF is grateful to the Merck Company Foundation for their continued financial support for these awards.

Deadline: September 23, 2013

For more information: Email Julia Berman or call 800-253-4636, ext. 6648.

ALS Therapy Alliance Grants Program

Thank you for your interest in submitting a proposal for grant funding to the ALS Therapy Alliance (ATA). Our organization traditionally awards grants from one to three years in term ranging from $100,000 to $1 million in funding to both non- and for-profit companies. National and international companies are eligible to apply.

The following outline will help you prepare the information needed for our next funding review, which happens twice a year in April and November.

Please note grant submission deadlines and number of copies requested in order to ensure timely processing of your application. The ALS Therapy Alliance does not cover indirect costs.

If you have questions about the submission process or this application, please contact Ray Bisson, Grants Manager at (603) 664-5005 or ray@alstherapyalliance.org, or visit our FAQ page.

http://alstherapyalliance.org/index.php/research/grant-submission-process/faqs.html

What to include with your grant proposal

ATA grant applications should follow the following format and adhere strictly to the maximum page limits (using only 11 point font or greater):

■ Abstract (1 page)

■ Background and Significance (2 pages)

■ Preliminary Data (2 pages)

■ Experimental Plan (3 pages)

■ References (no limit)

■ Budget

■ Budget Justification

■ NIH Biosketch (including present and pending support, 4 pages maximum) for PI's, post-docs and others involved in the project (excluding laboratory technicians)

■ Letters of collaboration and support

Grant proposal submission deadlines

To have your grant proposal reviewed at our April meeting, please submit by March 15th. To have your grant proposal reviewed at our November meeting, please submit by October 15th.

Where to send your grant proposal

Please email your proposal in PDF format to ray@alstherapyalliance.org.

Call for Applications: Meso Foundation Research Grants

The Meso Foundation (formerly known as MARF) is the non-profit dedicated to ending the suffering caused by mesothelioma. We are the international collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to:

·  Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso treatment specialists, and providing them assistance, emotional support and community with others;

·  Raise awareness of meso, and advocate that the public and private sectors partner in the effort to cure it by directing the resources needed to stop this global tragedy; and

·  Fund the highest quality and most promising meso research projects from around the world through rigorous peer-review. To date we have funded 86 projects, from six different countries, totaling over 8.2 million dollars.

The Meso Foundation offers research grants for two years up to $50,000 per year. Eligible projects may relate to benchwork, translational or clinical research that is not presently funded or pending review and may be conducted through any not-for-profit academic, medical or research institution. The Foundation will review and monitor the project's progress and results, requiring semi-annual disposition of funds reports, a ten month progress report, a presentation at the Foundation’s Symposium and a full progress report at the close of the project. The Foundation seeks exceptional projects for which the Foundation's funding is demonstrated to be essential and not duplicative. Please be advised that the Foundation does not pay institutional indirect costs.

Funded researchers will also be entitled to facilitated access to the National Mesothelioma Virtual Bank (NMVB),www.mesotissue.org.They will receive expedited review of requests to use the NMVB, and they will have direct, no-cost access to materials in the bank, as well as enhanced collections from the main sites of materials.

Encouraged projects include, but are not limited to, investigations of:

1. Strategies for early detection of new or progressive disease;

2. Definition of targetable differences between normal and transformed mesothelium and development of novel strategies for treatment;

3. Therapeutic intervention, including but not limited to;

a. Immune Response Targeted Therapy

b. Novel chemotherapeutic compounds

c. Novel radiation or surgical techniques

4. Determination of clinical/molecular determinants for prognosis

Applications will be considered for funding by the Meso Foundation’s Science Advisory Board comprised of doctors and researchers who work around the world within the mesothelioma field. These members will review and score the research proposals based on the following criteria. The applications will be ranked numerically and the highest scoring projects will be recommended to the Foundation’s Board of Directors for funding. Based on the funding available, awards will be granted.

Applications will be evaluated on the following criteria:

Significance - Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Investigator(s)- Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Innovation - Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Approach - Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, justified in terms of the scientific goals and research strategy proposed?

Environment - Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

Applications should be submittedthrough proposalCENTRAL.You will find the Mesothelioma Applied Research Foundation listed with the instructions and the application required. Applications are limited to 10 pages (not including biographies) and are due no later than August 2, 2013. Final award decisions will be made in December 2013 and all applicants will be notified of the outcome.

Travel Grants for the 4th International Thymic Malignancy Interest Group Annual Meeting (ITMIG 2013)

September 6 - 7, 2013 Bethesda, Maryland

This important Conference will highlight the latest scientific and clinical developments related to the management of thymic malignancies and will bring together established scientists and clinicians from all over the world who have interest in the field of thymic cancers research.

The Conference is pleased to offer travel grants to trainees, residents and fellows.

Eligible Candidates

Trainee, resident or fellow - proof of status required

Submitting and presenting author for an abstract accepted at ITMIG 2013

Benefits

Complimentary full Conference registration

Cash award to help offset travel expenses

Supporting Application Materials

Curriculum Vitae
Recommendation/Supporting Letter from supervisor
Proof of status (trainee, resident, fellow)

How to Apply?

Send application email including supporting materials to itmig2013@icsevents.com by June 14, 2013

Submit abstract via online abstract submission form by June 14, 2013

Terms and Conditions

The organizers reserve the right to

Cancel the scholarship if a selected award winner is not attending in person

Amend the terms and conditions of the scholarship program without notice

Deadlines and Timelines

Application Deadline: June 14, 2013

Notifications: expected to be available end of July 2013

Contact

For any questions or inquries regarding travel grants, please contact the Conference Secretariat at itmig2013@icsevents.com.

Gilead Sciences Research Scholars Program in Cystic Fibrosis

Application Deadline: July 26, 2013

The mission of the Gilead Sciences Research Scholars Program in Cystic Fibrosis is to support innovative scientific research that will advance knowledge in the fields of pediatric and adult cystic fibrosis and provide support for early research career development. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding of cystic fibrosis.

The Program provides financial support to 3 junior faculty researchers for a 2-year period. Each award is funded up to $130,000, to be paid in annual installments of up to $65,000 per year for 2 years. Funding for the second year is contingent upon submission of a progress report and approval by the Scientific Review Committee Chair.

Recipients of these competitive awards will be selected by a Committee comprised of leaders in the field of cystic fibrosis (the "Scientific Review Committee" or the "Committee"). The Committee will review complete applications and select research proposals based on their scientific merit, feasibility, mentorship, environment, and candidate. Announcement of award recipients will be made at an awards dinner hosted by the Committee and senior representatives from Gilead.

Applicants must meet the eligibility criteria in order to be considered for an award.

Eligibility

This award is intended for junior faculty who are in the early stages of their career; specifically, the Applicant may be the recipient of a career development (K) award, or another mentored research award, but not an RO1 grant or equivalent.

Applicants must meet the following requirements:

Hold an MD, DO, PhD, or equivalent degree at time of award

Be within 7 years of a faculty appointment, or an assistant professor, in association with a research institution in the United States at the time of application

Have a strong career interest in cystic fibrosis

Have a research mentor with extensive experience in the field of cystic fibrosis

Be able to devote at least 50% of professional time to research (versus administrative, patient care, or teaching responsibilities)

Be able to complete the proposed research within the 2-year award period, providing evidence (manuscript, presentation, or abstracts) for future research projects

Citizenship

An Applicant must be a citizen or permanent resident of the United States or hold a temporary nonimmigrant visa. This visa must be valid for the two-year award period (January 2, 2014 – December 31, 2015).

For general inquires about the Research Scholars Program, please call or email:

Gilead Sciences Research Scholars Program in Cystic Fibrosis

Attn: Research Scholars Program Coordinator

Telephone: 646-674-1820
Email: cfresearchscholars@contacthmc.com

If you are experiencing technical difficulties, please contact Zoomedia at 901-210-9564. If you have any other questions, please contact the Research Scholars Program Coordinator at 646-474-1820.